Senate Bill No. 80, identified as File No. 94, is a legislative proposal aimed at addressing the shortage of certain drugs prescribed to treat Type II diabetes, specifically dulaglutide and semaglutide. The bill mandates the Commissioner of Consumer Protection to adopt regulations to ensure an adequate supply of these drugs for patients diagnosed with Type II diabetes in the state. The regulations may include provisions that prohibit pharmacists from dispensing these drugs for off-label uses—conditions for which the drugs have not been approved by the Food and Drug Administration (FDA)—while they are in short supply within the state. The terms "dispense," "drug," and "pharmacist" are to be defined as per section 20-571 of the general statutes.

The bill is effective upon passage and does not have any fiscal impact on the state or municipal budgets, as the Consumer Protection agency is deemed to have the necessary expertise to implement the requirements of the bill without additional costs. The bill's urgency is underscored by the inclusion of dulaglutide and semaglutide on the FDA’s Drug Shortages list, due to increased global demand after clinical trials indicated weight loss benefits when these drugs are prescribed off-label to non-diabetic patients. The General Law Committee has given a Joint Favorable report on the bill with a unanimous vote of 23 to 0 on March 2, 2023.